WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a marketing and distribution agreement with Pfizer Inc. (NYSE: PFE), the world’s leading biopharmaceutical company, to provide certain Pfizer-developed genetically modified research models to the global biomedical research community. Under this agreement, Charles River will supply a number of pre-competitive, transgenic research models developed by Pfizer across a broad range of therapeutic areas, including neuroscience, diabetes and cardiovascular disease.
